The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)
Study Details
Study Description
Brief Summary
The Ear-Nose-Throat (ENT) Prospective International Cohort of patients with Primary Ciliary Dyskinesia (EPIC-PCD) is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients keep being managed according to local procedures and guidelines.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The EPICD-PCD is hosted at the Institute of Social and Preventive Medicine (ISPM) at the University of Bern, Switzerland. Research is performed in close collaboration with all data contributors. This study aims to characterise ENT disease in PCD patients and its association with lower respiratory disease, and to identify determinants of its prognosis.
The investigators aim to:
-
Assess the prevalence and severity of sinonasal and otologic symptoms and the frequency and range of signs and physiological findings assessed during standardised ENT physical examination, and describe differences by age;
-
Study the association of sinonasal and otologic disease with lower respiratory disease in PCD patients;
-
Identify determinants of disease course and prognosis of sinonasal and otologic disease in PCD patients.
Study design:
The EPIC-PCD is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients will keep being managed according to local procedures and guidelines.
Patients with PCD are followed regularly at each centre, at 3-month to 6-month intervals. Each patient undergoes a detailed ENT sinonasal and otologic examination by ENT specialists, at minimum once a year, during a programmed follow-up visit. Additional ENT examinations are performed if indicated during in-between follow-up visits. Patients will not be subjected to additional invasive measurements solely for the purposes of the study.
What information is collected:
The study collect clinical data from patients assessment at regular consultations at the outpatient clinics.
For the collection of clinical data, participating centres will use FOLLOW-PCD, a disease-specific form for standardised prospective data collection during routine clinical follow-up of PCD patients.
Study database:
The EPIC-PCD database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.
How to participate:
Centres that wish to participate to the project and contribute data can contact the EPIC-PCD managing centre to sign a data delivery agreement. They then will receive a password to access the online software REDCap and they will be able to enter their data directly. They can also upload follow-up data or add additional patients at a later time point.
Funding:
The setting up of the EPIC-PCD (salaries, consumables and equipment) was funded by the Swiss National Science Foundation. Data collection and management at each site was funded according to local arrangements. Most participating researchers and data contributors participate in the European Respiratory Society Clinical Research collaboration "Better Evidence to Advance Therapeutic options for PCD" (BEAT-PCD) (https://beat-pcd.squarespace.com/). Infrastructure is provided for free by the University of Bern, where the data are pooled and stored.
Study Design
Outcome Measures
Primary Outcome Measures
- Sinonasal symptoms and signs [at baseline]
Prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring
- Course of sinonasal symptoms and signs (year 1) [at 12 months from recruitment]
Change from baseline prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring, at 12 months
- Course of sinonasal symptoms and signs (year 2) [at 24 months from recruitment]
Change from baseline prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring, at 24 months
- Otological symptoms and signs [at baseline]
Prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge
- Course of otological symptoms and signs (year 1) [at 12 months from recruitment]
Change from baseline prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge, at 12 months
- Course of otological symptoms and signs (year 2) [at 24 months from recruitment]
Change from baseline prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge, at 24 months
- Nasal endoscopy (description of nasal mucosa) [at baseline]
Description of nasal mucosa as seen via nasal endoscopy examination
- Nasal endoscopy (changes of nasal mucosa at year 1) [at 12 months from recruitment]
Changes in nasal mucosa from baseline as seen via nasal endoscopy examination at 12 months
- Nasal endoscopy (changes of nasal mucosa at year 2) [at 24 months from recruitment]
Changes in nasal mucosa from baseline as seen via nasal endoscopy examination at 24 months
- Nasal endoscopy (nasal polyps) [at baseline]
Prevalence of nasal polyps at baseline
- Nasal endoscopy (nasal polyps at year 1) [at 12 months from recruitment]
Changes in prevalence of nasal polyps from baseline to 12 months
- Nasal endoscopy (nasal polyps at year 2) [at 24 months from recruitment]
Changes in prevalence of nasal polyps from baseline to 24 months
- Sinonasal examination (Lidholdt score) [at baseline]
Lidholdt score at baseline
- Sinonasal examination (Lidholdt score at year 1) [at 12 months from recruitment]
Changes in Lidholdt score from baseline to 12 months
- Sinonasal examination (Lidholdt score at year 2) [at 24 months from recruitment]
Changes in Lidholdt score from baseline to 24 months
- Ear examination (ear discharge) [at baseline]
Prevalence of ear discharge at baseline
- Ear examination (ear discharge at year 1) [at 12 months from recruitment]
Changes in prevalence of ear discharge from baseline to 12 months
- Ear examination (ear discharge at year 2) [at 24 months from recruitment]
Changes in prevalence of ear discharge from baseline to 24 months
- Otoscopy (description of the tympanic membrane) [at baseline]
Description of tympanic membrane as seen via otoscopy examination
- Otoscopy (description of the tympanic membrane at year 1) [at 12 months from recruitment]
Changes in the tympanic membrane from baseline to 12 months as seen via otoscopy examination
- Otoscopy (description of the tympanic membrane at year 2) [at 24 months from recruitment]
Changes in the tympanic membrane from baseline to 24 months as seen via otoscopy examination
- Tympanometry [at baseline]
Results of tympanometry (tympanogram type for both ears) at baseline
- Tympanometry (at year 1) [at 12 months from recruitment]
Changes in tympanogram (for both ears) from baseline to 12 months
- Tympanometry (at year 2) [at 24 months from recruitment]
Changes in tympanogram (for both ears) from baseline to 24 months
- Audiometry [at baseline]
Results of audiometry: type of audiometry and results based on WHO hearing loss grades (for both ears)
- Audiometry (at year 1) [at 12 months from recruitment]
Changes in audiometry results from baseline to 12 months
- Audiometry (at year 2) [at 24 months from recruitment]
Changes in audiometry results from baseline to 24 months
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of PCD (clinical and test certified)
-
Patient must undergo an ENT examination minimum once a year as part of their clinical follow-up
Exclusion Criteria:
None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Bern | Bern | Switzerland |
Sponsors and Collaborators
- University of Bern
- Bicetre Hospital
- Centre Hospitalier Intercommunal Creteil
- University Hospital Southampton NHS Foundation Trust
- Universitaire Ziekenhuizen Leuven
- Amsterdam UMC, location VUmc
- University of Cyprus
- Hacettepe University
- Marmara University
- Hospital Universitario La Fe
- University Hospital Inselspital, Berne
Investigators
- Principal Investigator: Myrofora Goutaki, MD-PhD, University of Bern
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EPIC-PCD